/RADX

RADX Stock - Radiopharm Theranostics Limited

Q: What is the analyst price target for RADX?

Analyst price target information is not currently available for RADX.

Q: What is RADX's market cap?

Market capitalization information is not currently available for RADX.

Healthcare|Biotechnology|NASDAQ

$5.19-5.46%

$0.30 (-5.46%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+169.7%upside

Target: $14.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RADX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.90

52W High$16.25

52W Low$3.50

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	$3.63M	$299,228	$292,359	$8,831
Gross Profit	$39,276	$299,228	$292,359	$8,831
Gross Margin	1.1%	100.0%	100.0%	100.0%
Operating Income	$-38,173,865	$-36,620,852	$-34,508,085	$-19,916,352
Net Income	$-38,342,457	$-47,949,119	$-34,611,194	$-30,338,979
Net Margin	-1055.3%	-16024.3%	-11838.6%	-343550.9%
EPS	$-5.28	$-36.00	$-33.00	$-29.76

Company Overview

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$15

Average Target

↑ 189.0% Upside

Now

$15

Low

$15

Average

$15

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 12th 2025	B. Riley Securities	Initiation	Buy	$15

Frequently Asked Questions about RADX

What is RADX's current stock price?

Radiopharm Theranostics Limited (RADX) is currently trading at $5.19 per share. The stock has moved -5.46% today.

What is the analyst price target for RADX?

The average analyst price target for RADX is $14.00, based on 1 analyst.

What sector is Radiopharm Theranostics Limited in?

Radiopharm Theranostics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RADX's market cap?

Radiopharm Theranostics Limited has a market capitalization of $0.01 billion, making it a small-cap company.

Does RADX pay dividends?

No, Radiopharm Theranostics Limited does not currently pay a dividend to shareholders.